Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 11/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 8/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | GOT1 | P17174 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | IDH2 | P48735 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17618783 | 0.92 | MEN1 (0.47) | TRPV1GOT1KITMEN1ALDH1A1 | |
| SCHEMBL17618348 | 0.89 | IDH2 (0.45) | TRPV1MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL17618409 | 0.89 | LRRK2 (0.40) | SCN10ALRRK2TRPV1GOT1KIT | |
| SCHEMBL17618796 | 0.89 | MEN1 (0.45) | TRPV1MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL17618902 | 0.88 | CA2 (0.42) | TRPV1MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL17618906 | 0.88 | CA2 (0.42) | TRPV1MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL17618820 | 0.87 | MEN1 (0.43) | TRPV1MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL17618786 | 0.87 | FYN (0.42) | TRPV1KITMEN1ALDH1A1KMT2A | |
| SCHEMBL17618358 | 0.87 | RPS6KB1 (0.40) | TRPV1KITMEN1ALDH1A1KMT2A | |
| SCHEMBL20632093 | 0.86 | MEN1 (0.43) | TRPV1GOT1KITMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | SCN10A 3878/4885LRRK2 533/4885SCN8A 4263/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | SCN10A 3878/4885LRRK2 533/4885SCN8A 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.